India, April 17 -- Psyence Biomedical Ltd. (PBM) said it supports emerging U.S. executive efforts to advance regulated research into Ibogaine, a naturally occurring psychedelic compound being studied for post-traumatic stress disorder (PTSD), addiction, and other serious mental health conditions.
Ibogaine remains a Schedule I substance in the U.S., and patients often seek unregulated access abroad. The anticipated federal action signals growing recognition of the need for controlled evidence-based research into new therapeutic options, particularly for treatment-resistant conditions.
"As global interest in Ibogaine accelerates, structured research and regulated development pathways are essential to improving both patient safety and long-t...